Endocrine and metabolic aspects of adult Prader-Willi syndrome with special emphasis on the effect of growth hormone treatment.

What Was Tested

Researchers studied Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in this randomized controlled trial publication.

Prader-Willi syndrome (PWS) is a genetic disorder characterized by mild mental retardation, short stature, abnormal body composition, muscular hypotonia and distinctive behavioural features.

In the PWS genotype loss of one or more normally active paternal genes in region q11-13 on chromosome 15 is seen.

Who Took Part

The abstract describes 19 adults taking part.

By PubMed's age tags, the people studied were teenagers and adults, both men and women.

How the Study Was Run

The design is described as randomized and pilot.

Because people in this Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

It is described as a pilot, a small early test of whether a larger Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study would be practical.

What Was Measured

At baseline the activity of the GH-insulin-like growth factor-I (IGF-I) system was impaired with low GH values, low total IGF-I and in relation to the obesity low levels of free IGF-I and non-suppressed IGF-binding-protein-1 (IGFBP-1). 2/3 were hypogonadal.

Four patients had impaired glucose tolerance and nine patients high homeostasis model assessment (HOMA) index, indicating insulin resistance.

PubMed files the paper under topics including Appetite, Body Composition, Bone Density, Carbohydrate Metabolism, DNA Methylation, Endocrine System and Ghrelin.

What This Means in Plain Language

The paper is a randomized and pilot study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 19 adults.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 2004 (Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society), a journal based in Scotland.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.